Beyond oncology - Application of HPMA copolymers in non-cancerous diseases

被引：37

作者：

Liu, Xin-Ming ^{[1
]}

Miller, Scott C. ^{[2
]}

Wang, Dong ^{[1
]}

机构：

[1] Univ Nebraska, Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA

[2] Univ Utah, Dept Radiol, Div Radiobiol, Salt Lake City, UT 84112 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2010年 / 62卷 / 02期

关键词：

HPMA copolymers; Musculoskeletal diseases; Infectious diseases; Arthritis; Bone-targeting; Central nervous system (CNS); DRUG-DELIVERY SYSTEM; OVARIAN-CARCINOMA CELLS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD REPAIR; HEPATITIS-B-VIRUS; RHEUMATOID-ARTHRITIS; N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS; CATHEPSIN-K; VISCERAL LEISHMANIASIS; ANTISENSE OLIGONUCLEOTIDES;

D O I：

10.1016/j.addr.2009.10.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：258 / 271

页数：14